Fibrinolysin

Jump to: navigation, search
Fibrinolysin
Clinical data
Pregnancy
category
  • C
Routes of
administration
ointment for local application, in combination with desoxyribonuclease
ATC code
Legal status
Legal status
  • Rx only (where available)
Pharmacokinetic data
Bioavailabilityvirtually none
Metabolismlocal inactivation
Elimination half-lifealmost completely inactivated after 24 hours
Identifiers
CAS Number
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass~ 13,800 g/mol

WikiDoc Resources for Fibrinolysin

Articles

Most recent articles on Fibrinolysin

Most cited articles on Fibrinolysin

Review articles on Fibrinolysin

Articles on Fibrinolysin in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Fibrinolysin

Images of Fibrinolysin

Photos of Fibrinolysin

Podcasts & MP3s on Fibrinolysin

Videos on Fibrinolysin

Evidence Based Medicine

Cochrane Collaboration on Fibrinolysin

Bandolier on Fibrinolysin

TRIP on Fibrinolysin

Clinical Trials

Ongoing Trials on Fibrinolysin at Clinical Trials.gov

Trial results on Fibrinolysin

Clinical Trials on Fibrinolysin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Fibrinolysin

NICE Guidance on Fibrinolysin

NHS PRODIGY Guidance

FDA on Fibrinolysin

CDC on Fibrinolysin

Books

Books on Fibrinolysin

News

Fibrinolysin in the news

Be alerted to news on Fibrinolysin

News trends on Fibrinolysin

Commentary

Blogs on Fibrinolysin

Definitions

Definitions of Fibrinolysin

Patient Resources / Community

Patient resources on Fibrinolysin

Discussion groups on Fibrinolysin

Patient Handouts on Fibrinolysin

Directions to Hospitals Treating Fibrinolysin

Risk calculators and risk factors for Fibrinolysin

Healthcare Provider Resources

Symptoms of Fibrinolysin

Causes & Risk Factors for Fibrinolysin

Diagnostic studies for Fibrinolysin

Treatment of Fibrinolysin

Continuing Medical Education (CME)

CME Programs on Fibrinolysin

International

Fibrinolysin en Espanol

Fibrinolysin en Francais

Business

Fibrinolysin in the Marketplace

Patents on Fibrinolysin

Experimental / Informatics

List of terms related to Fibrinolysin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Fibrinolysin is an enzyme derived from plasma of bovine origin or extracted from cultures of certain bacteria. It is used locally only and exclusively together with the enzyme desoxyribonuclease (extracted from bovine pancreas). Fibrinolysin and desoxyribonuclease both act as lytic enzymes. The combination is available as ointment containing 1 BU (Biological Unit) fibrinolysin and 666 BUs desoxyribonuclease per gram.

Fibrinolysin attacks and inactivates fibrin molecules occurring in undesirable exudates on the surface of the human body and on human mucosa, e.g., in superficial wounds and burns, while desoxyribonuclease targets and destroys (human) DNA. The combination of the two enzymes has a synergistic effect on necrotic but not on living tissue. According to the manufacturer the ointment provides enhanced wound cleaning and accelerates the healing process.

Both enzymes are marginally resorbed into systemic circulation because of their very high molecular weight and their macromolecular structure.

The activity of both enzymes is almost completely exhausted after 24 hours. Usually, it is necessary to repeat the application (and renew the dressing) every 6 to 8 hours until healing becomes complete.

The ointment is marketed by Pfizer under the brand name Fibrolan® in a variety of countries (e.g. Switzerland). It is currently not approved in the USA.

Where approved, Fibrolan® has been licensed on the basis of claimed good therapeutical experience, but adequate and well controlled studies are still lacking.

In the past, combinations with the antibiotic chloramphenicol were available, but because chloramphenicol in any form of application has led to aplastic anemia and death, these were banned. Additionally, combinations with the antifibrinolytic agent tranexamic acid have been withdrawn from pharma markets.

Indications

Enzymatic wound cleaning to assist healing of minor burns, superficial wounds, ulcus cruris, and superficial hematoma.

Contraindications and Precautions

The ointment should not be used in patients with a known hypersensitivity to any ingredient. It should be used with caution in patients with hypersensitivity to bovine proteins in general and in pregnant women (category C), because no human data is available.

Side-Effects

Infrequently, local reactions such as increased pain or a stitching/burning sensation are noticed. No systemic anticoagulant activity has been seen due to the exclusively local character of treatment.

Interactions

Not known.

External References

References


Linked-in.jpg